HIGHLIGHTS
- who: Pilar Santiago-Setien et al. from the Sapienza University of Rome, Italy have published the research: Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study, in the Journal: (JOURNAL)
- what: All patients included in the study had been initially treated with natalizumab in standard regimen for at least 24 months and subsequently changed to an extended regimen due to safety reasons. The primary reason for switching to ocrelizumab was the concern of a high risk of PML.
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.